Clinical and Experimental Spinal Cord Injury Research Laboratory (Neuroparaplegiology), CHARITÉ Campus Mitte-University Medicine Berlin, Germany.
Spine (Phila Pa 1976). 2013 May 15;38(11):E669-77. doi: 10.1097/BRS.0b013e31828e4dce.
Written mail-out survey.
To determine current practice in high-dose methylprednisolone succinate (MPSS) administration for treatment of acute spinal cord injury (SCI) in Germany.
Reanalysis of the National Acute Spinal Cord Injury Studies (NASCIS) resulted in criticism of the use of high-dose MPSS for treatment of acute SCI. Subsequently, SCI treatment guidelines were revised leading to a reduction in MPSS use across North America. The impact of these revisions on SCI treatment in Germany is not known.
A questionnaire was sent to all trauma, orthopedic and neurosurgical departments of German university centers, affiliated teaching hospitals, and specialized SCI care centers. Survey included 6 questions about the administration of MPSS after acute SCI.
Three hundred seventy-two respondents completed the survey (response rate: 51% overall, 76% university hospitals, 85% specialized SCI care centers). Overall, 55% of departments that treat SCI prescribe MPSS. Among them, 73% are "frequent" users administering MPSS to more than 50% of their patients. Ten percent prescribe according to NASCIS I, 43% NASCIS II, 33% NASCIS III, and 13% "generic protocols." As justification for MPSS treatment, "effectiveness" ranked before "common practice" and "medicolegal reasons." "Specialized" SCI care centers differ in that (1) MPSS is administered less frequently, (2) NASCIS I doses are not used, and (3) during the past several years, practice patterns are more likely to have shifted away from the treatment of SCI with MPSS.
About one-half of the institutions continue to prescribe MPSS in the setting of acute SCI. A need for further education in almost one-fourth of German departments treating acute SCI is demonstrated through responses indicating use of the outdated NASCIS I protocol, a "legal need" or "unchanged MPSS application during the last years." "Specialized" SCI centers are more likely to change their practice in accordance with evolving literature.
书面邮件调查。
确定德国在使用大剂量琥珀酸甲泼尼龙(MPSS)治疗急性脊髓损伤(SCI)方面的当前实践。
对国家急性脊髓损伤研究(NASCIS)的重新分析导致了对使用大剂量 MPSS 治疗急性 SCI 的批评。随后,SCI 治疗指南进行了修订,导致北美 MPSS 的使用减少。这些修订对德国 SCI 治疗的影响尚不清楚。
向德国大学中心、附属医院和专门的 SCI 护理中心的所有创伤、骨科和神经外科部门发送了一份问卷。调查包括 6 个关于急性 SCI 后 MPSS 给药的问题。
372 名受访者完成了调查(总体应答率为 51%,大学医院为 76%,专门的 SCI 护理中心为 85%)。总体而言,55%的 SCI 治疗部门开具 MPSS 处方。其中,73%是“经常”使用者,给超过 50%的患者使用 MPSS。10%根据 NASCIS I 进行处方,43%根据 NASCIS II,33%根据 NASCIS III,13%根据“通用方案”。作为 MPSS 治疗的理由,“有效性”排在“常规做法”和“医疗法律原因”之前。“专门”的 SCI 护理中心的不同之处在于:(1)MPSS 的给药频率较低,(2)不使用 NASCIS I 剂量,(3)在过去几年中,实践模式更有可能从使用 MPSS 治疗 SCI 转变。
约有一半的机构在急性 SCI 情况下继续开具 MPSS 处方。近四分之一接受急性 SCI 治疗的德国部门的回应表明,他们仍在使用过时的 NASCIS I 方案、“法律需要”或“过去几年中不变的 MPSS 应用”,这表明需要进一步教育。“专门”的 SCI 中心更有可能根据不断发展的文献改变他们的实践。
3。